HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

sebetralstat

Also Known As:

KVD900; N-((3-fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-((4-((2-oxopyridin-1-yl)methyl)phenyl)methyl)pyrazole-4-carboxamide

Networked: 6 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - sebetralstat: 6

Experts

1.	De Donatis, Gian Marco: 2 articles (01/2022 - 01/2022)
2.	Duckworth, Edward J: 2 articles (01/2022 - 01/2022)
3.	Feener, Edward P: 2 articles (01/2022 - 01/2022)
4.	Hampton, Sally L: 2 articles (01/2022 - 01/2022)
5.	Li, Lily: 2 articles (01/2022 - 01/2022)
6.	Maetzel, Andreas: 2 articles (01/2022 - 01/2022)
7.	Murugesan, Nivetha: 2 articles (01/2022 - 01/2022)
8.	Rushbrooke, Louise J: 2 articles (01/2022 - 01/2022)
9.	Yea, Christopher M: 2 articles (01/2022 - 01/2022)
10.	Francombe, Danielle: 1 article (01/2022)

Related Diseases

1.

Hereditary Angioedemas

11/01/2023 - "Based on these results, a phase 3 trial to evaluate the efficacy and safety of two dose levels of sebetralstat in adolescent and adult participants with hereditary angioedema has been initiated (NCT05259917). "
09/01/2023 - "Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat."
01/01/2022 - "KVD900, an oral on-demand treatment for hereditary angioedema: Phase 1 study results."
11/01/2023 - "We aimed to assess the novel oral plasma kallikrein inhibitor, sebetralstat, which is in development, for on-demand treatment of hereditary angioedema attacks. "
07/01/2022 - "Sebetralstat is an investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. "

Related Drugs and Biologics

1.	Plasma Kallikrein
2.	sebetralstat